<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231084</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003491</org_study_id>
    <nct_id>NCT04231084</nct_id>
  </id_info>
  <brief_title>Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide</brief_title>
  <official_title>Acute Hemodynamic Comparison of Inhaled Nitric Oxide and Inhaled Epoprostenol in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this study is to examine the acute vasoreactive response to both
      inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally
      interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity
      to disease severity and PH phenotype.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean pulmonary artery pressure</measure>
    <time_frame>Pre-pulmonary vasodilator testing measurements (baseline) will be compared to post-pulmonary vasodilator testing measurements during diagnostic right heart catheterization.</time_frame>
    <description>The primary outcome will be change in mean pulmonary artery pressure (mmHg) from baseline to after 5-minutes of inhaled vasodilator.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vasodilator testing will be performed with inhaled nitric oxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Epoprostenol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vasodilator testing will be performed with inhaled epoprostenol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasodilator testing (Inhaled Nitric Oxide)</intervention_name>
    <description>Right heart catheterization with vasodilator testing with each arms' associated agent will be performed</description>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasodilator testing (Inhaled Epoprostenol)</intervention_name>
    <description>Right heart catheterization with vasodilator testing with each arms' associated agent will be performed</description>
    <arm_group_label>Inhaled Epoprostenol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mPAP ≥ 21mmHg, PAWP ≤ 25mmHg, and PVR ≥3 WU

          -  Classified as WHO group I-III pulmonary hypertension

        Exclusion Criteria:

          -  WHO group IV and V pulmonary hypertension

          -  Patients who are on baseline pulmonary vasodilator medications

          -  Severe aortic or mitral valve disease

          -  Patients who are pregnant

          -  Left ventricular ejection fraction of &lt;35%

          -  Patients who are hospitalized as inpatients at the time of RHC

          -  Patients with systolic blood pressure &lt;90mmHg or mean arterial pressure of &lt; 60mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron B Waxman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole F Ruopp, MD</last_name>
    <phone>617-525-9733</phone>
    <email>nruopp@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aaron B Waxman, MD</last_name>
    <phone>617-525-9733</phone>
    <email>abwaxman@bwh.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Aaron Waxman MD PhD</investigator_full_name>
    <investigator_title>Associate Professor of Pulmonary and Critical Care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoprostenol</mesh_term>
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
    <mesh_term>Vasodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

